309 related articles for article (PubMed ID: 25608583)
1. Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression.
Di Yacovo MS; Moltó J; Ferrer E; Curran A; Else L; Gisslén M; Clotet B; Tiraboschi JM; Niubò J; Vila A; Zetterberg H; Back D; Podzamczer D
J Antimicrob Chemother; 2015 May; 70(5):1513-6. PubMed ID: 25608583
[TBL] [Abstract][Full Text] [Related]
2. Plasma trough concentrations of darunavir/ritonavir and raltegravir in older patients with HIV-1 infection.
Calza L; Colangeli V; Magistrelli E; Bussini L; Conti M; Ramazzotti E; Mancini R; Viale P
HIV Med; 2017 Aug; 18(7):474-481. PubMed ID: 28116848
[TBL] [Abstract][Full Text] [Related]
3. Etravirine concentrations in CSF in HIV-infected patients.
Tiraboschi JM; Niubo J; Vila A; Perez-Pujol S; Podzamczer D
J Antimicrob Chemother; 2012 Jun; 67(6):1446-8. PubMed ID: 22357802
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of once-daily darunavir/ritonavir in HIV-1-infected pregnant women.
Crauwels HM; Kakuda TN; Ryan B; Zorrilla C; Osiyemi OO; Yasin S; Brown K; Verboven P; Hillewaert V; Baugh B
HIV Med; 2016 Oct; 17(9):643-52. PubMed ID: 27187894
[TBL] [Abstract][Full Text] [Related]
5. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study.
Molina JM; Clotet B; van Lunzen J; Lazzarin A; Cavassini M; Henry K; Kulagin V; Givens N; de Oliveira CF; Brennan C;
Lancet HIV; 2015 Apr; 2(4):e127-36. PubMed ID: 26424673
[TBL] [Abstract][Full Text] [Related]
6. Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1.
Ghosn J; Slama L; Chermak A; Houssaini A; Lambert-Niclot S; Schneider L; Fourn E; Duvivier C; Simon A; Courbon E; Murphy R; Flandre P; Peytavin G; Katlama C;
J Med Virol; 2013 Jan; 85(1):8-15. PubMed ID: 23024008
[TBL] [Abstract][Full Text] [Related]
7. Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial.
Pressiat C; Hirt D; Treluyer JM; Zheng Y; Morlat P; Naqvi A; Tran L; Viard JP; Avettand-Fenoel V; Rouzioux C; Meyer L; Cheret A;
J Antimicrob Chemother; 2018 Apr; 73(4):1020-1024. PubMed ID: 29365125
[TBL] [Abstract][Full Text] [Related]
8. Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics.
Calcagno A; Yilmaz A; Cusato J; Simiele M; Bertucci R; Siccardi M; Marinaro L; D'Avolio A; Di Perri G; Bonora S
AIDS; 2012 Jul; 26(12):1529-33. PubMed ID: 22555164
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naïve HIV-1-infected individuals.
Jackson A; Else L; Higgs C; Karolia Z; Khoo S; Back D; Devitt E; Pozniak A; Boffito M
HIV Clin Trials; 2018 Feb; 19(1):31-37. PubMed ID: 29189101
[TBL] [Abstract][Full Text] [Related]
10. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.
Clotet B; Feinberg J; van Lunzen J; Khuong-Josses MA; Antinori A; Dumitru I; Pokrovskiy V; Fehr J; Ortiz R; Saag M; Harris J; Brennan C; Fujiwara T; Min S;
Lancet; 2014 Jun; 383(9936):2222-31. PubMed ID: 24698485
[TBL] [Abstract][Full Text] [Related]
11. DRV concentrations and viral load in CSF in patients on DRV/r 600/100 or 800/100mg once daily plus two NRTI.
Di Yacovo S; Molto J; Ferrer E; Curran A; Else LJ; Clotet B; Tiraboschi J; Niubo J; Vila A; Podzamczer D
J Int AIDS Soc; 2014; 17(4 Suppl 3):19821. PubMed ID: 25397565
[TBL] [Abstract][Full Text] [Related]
12. Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.
Bickel M; Bodtländer A; Knecht GK; Stephan C; von Hentig N; Kurowski M; Gute P; Klauke S; Lutz T
J Antimicrob Chemother; 2009 Dec; 64(6):1260-4. PubMed ID: 19776037
[TBL] [Abstract][Full Text] [Related]
13. Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay.
Charpentier C; Choquet M; Joly V; Yeni P; Visseaux B; Caseris M; Brun-Vézinet F; Yazdanpanah Y; Peytavin G; Descamps D; Landman R
J Antimicrob Chemother; 2014 Oct; 69(10):2819-25. PubMed ID: 24948705
[TBL] [Abstract][Full Text] [Related]
14. Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients.
Calza L; Danese I; Colangeli V; Manfredi R; Magistrelli E; Verucchi G; Conti M; Motta R; Viale P
Infect Dis (Lond); 2015 Sep; 47(9):625-36. PubMed ID: 25875396
[TBL] [Abstract][Full Text] [Related]
15. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
[TBL] [Abstract][Full Text] [Related]
16. Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir.
Bartels H; Decosterd L; Battegay M; Marzolini C
J Antimicrob Chemother; 2017 Sep; 72(9):2574-2577. PubMed ID: 28575323
[TBL] [Abstract][Full Text] [Related]
17. Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients.
Moltó J; Valle M; Santos JR; Mothe B; Miranda C; Cedeño S; Negredo E; Yritia M; Videla S; Barbanoj MJ; Clotet B
Antivir Ther; 2010; 15(2):219-25. PubMed ID: 20386077
[TBL] [Abstract][Full Text] [Related]
18. Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial.
Overton ET; Tebas P; Coate B; Ryan R; Perniciaro A; Dayaram YK; De La Rosa G; Baugh BP
HIV Clin Trials; 2016 Mar; 17(2):72-7. PubMed ID: 26917112
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of once-daily dolutegravir and ritonavir-boosted darunavir in HIV patients: the DUALIS study.
Spinner CD; Kümmerle T; Krznaric I; Degen O; Schwerdtfeger C; Zink A; Wolf E; Klinker HHF; Boesecke C
J Antimicrob Chemother; 2017 Sep; 72(9):2679-2681. PubMed ID: 28859438
[No Abstract] [Full Text] [Related]
20. Abacavir/lamivudine plus darunavir/ritonavir in routine clinical practice: a multicentre experience in antiretroviral therapy-naive and -experienced patients.
Podzamczer D; Imaz A; Perez I; Viciana P; Valencia E; Curto J; Martín T; Castaño M; Rojas J; Espinosa N; Moreno V; Asensi V; Iribarren JA; Clotet B; Force L; Bachiller P; Knobel H; López Bernaldo De Quirós JC; Blanco JR; Rozas N; Vergas J; Ocampo A; Camacho A; Flores J; Gomez-Sirvent JL;
J Antimicrob Chemother; 2014 Sep; 69(9):2536-40. PubMed ID: 24833755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
